Eid Michal, Bednaříková Markéta, Vlažný Jakub, Hausnerová Jitka, Taslerová Renata, Vilmanová Sára, Jelínková Martina, Homolová Alena, Gryc Martin, Trizuljak Jakub, Pavlovský Zdeněk, Tuček Štěpán, Brančíková Dagmar, Bratová Monika, Rohan Tomáš, Kala Zdeněk, Král Zdeněk, Mayer Jiří, Svobodník Adam, Slabý Ondřej
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Center for Precision Medicine, University Hospital Brno, Brno, Czech Republic.
Cancer Med. 2025 Aug;14(15):e71119. doi: 10.1002/cam4.71119.
Molecular tumor boards (MTBs) support the development of personalized treatment strategies for patients with various cancer types based on comprehensive genomic profiling (CGP) of tumor tissue. Despite the unprecedented results demonstrated in many molecularly driven clinical trials, access to matched therapy remains a significant challenge in routine clinical practice worldwide.
In this study, we analyzed the MTB cohort from University Hospital Brno in the Czech Republic. Between February 2021 and April 2025, a total of 553 cancer patients with limited therapeutic options underwent CGP of tumor tissue and were subsequently presented at the MTB.
The median age of the patients was 61.1 years, and 62.2% were female. The most frequently tested diagnoses were colorectal cancer (n = 88; 15.9%), cholangiocarcinoma (n = 66; 11.9%), and pancreatic cancer (n = 65; 11.8%). The median number of prior lines of standard systemic therapy before CGP testing was two. MTB-recommended matched therapy for 326 (59.0%) out of 553 tested patients, based on 545 unique molecular alterations. The most frequently recommended drugs included immunotherapy (162/545; 29.7%), tyrosine kinase inhibitors (140/545; 25.7%), and poly (ADP-ribose) polymerase inhibitors (63/545; 11.6%). Reimbursement was requested from healthcare insurance providers in 115 cases, with 87 (75.7%) approvals. Together with other reimbursement forms, a total of 96 (17.4%) out of 553 patients initiated matched therapy. A progression-free survival ratio (PFS2/PFS1) of ≥ 1.3 was observed in 29 (41.4%) of the 70 evaluable pretreated patients.
This is the first study to report on a real-world MTB cohort from the Czech Republic, demonstrating a diagnostic yield comparable to previously published studies, good availability of recommended drugs, and clinical benefit in evaluable patients.
分子肿瘤委员会（MTB）基于肿瘤组织的全面基因组分析（CGP），为患有各种癌症类型的患者制定个性化治疗策略。尽管在许多分子驱动的临床试验中取得了前所未有的成果，但在全球范围内的常规临床实践中，获得匹配的治疗方案仍然是一项重大挑战。
在本研究中，我们分析了捷克布尔诺大学医院的MTB队列。在2021年2月至2025年4月期间，共有553名治疗选择有限的癌症患者接受了肿瘤组织的CGP检测，随后在MTB会议上进行了展示。
患者的中位年龄为61.1岁，女性占62.2%。检测频率最高的诊断为结直肠癌（n = 88；15.9%）、胆管癌（n = 66；11.9%）和胰腺癌（n = 65；11.8%）。在进行CGP检测之前，标准全身治疗的既往治疗线数中位数为2。基于545种独特的分子改变，MTB为553名检测患者中的326名（59.0%）推荐了匹配的治疗方案。最常推荐的药物包括免疫疗法（162/545；29.7%）、酪氨酸激酶抑制剂（140/545；25.7%）和聚（ADP - 核糖）聚合酶抑制剂（63/545；11.6%）。115例病例向医疗保险提供商申请了报销，其中87例（75.7%）获得批准。连同其他报销形式，553名患者中共有96例（17.4%）开始了匹配治疗。在70例可评估的预处理患者中，29例（41.4%）观察到无进展生存率（PFS2/PFS1）≥1.3。
这是第一项报道来自捷克共和国的真实世界MTB队列的研究，显示出与先前发表的研究相当的诊断率、推荐药物的良好可及性以及可评估患者的临床获益。
